Introduction

Amendments 1 to the Health Insurance
Portability and Accountability Act of 1996 (HIPAA) 2 Privacy Rule 3 in 2014 generated ongoing controversy by granting people a legal right to obtain their test results directly from HIPAAcovered laboratories. This HIPAA access right 4 applies to many types of laboratory test results but has been especially controversial with respect to genomic data, the focus of this commentary. The access right potentially includes not just confirmed, clinically significant genomic test results but also uninterpreted variants and variants of uncertain significance. 5 With limited exceptions, it applies to data stored at HIPAA-covered facilities, potentially including some research laboratories. [6] [7] [8] Placing genomic research results into laypeople's hands leaves many bioethicists, physicians, and safety regulators uncomfortable, reflecting concerns that research data could be of subclinical quality in the sense of lacking analytic validity, clinical validity, and/or clinical actionability or being prone to ''mix-ups'' where one person's test results are wrongly attributed to another person. [9] [10] [11] The National Academies recently launched a study that people hope might help clarify matters. 12 The generally accepted consumer safety regulatory paradigm blocks consumers' access to health-related data unless the data meet quality standards appropriate for clinical care. This paradigm informs how the Food and Drug Administration (FDA) oversees medical devices, how the Centers for Medicare and Medicaid Services (CMS) oversees clinical laboratories under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 13 and how many bioethicists view the return of incidental findings and individual research results. [9] [10] [11] Viewed through the lens of consumer safety regulation, the HIPAA access right seems strange and ill advised, but this commentary explains why that is not the correct lens through which to view it. This commentary positions the HIPAA right of access to genomic data as a federal civil-rights regulation issued in response to a mandate that Congress laid down in the Genetic Information Nondiscrimination Act of 2008 (GINA). 14 Civil rights enjoy special protection in the American system of law, but there are legally permissible pathways for addressing valid safety concerns that surround individual access to genomic test results.
The Development of Genomic Civil Rights
The passage of GINA expanded the United States' federal regulatory program for genetic and genomic testing to include civil-rights and consumer safety regulations. GINA is best known for banning discrimination in employment and health insurance. 15 Its broader sweep as a civil-rights law is less well understood. Section 102(a)(4) of GINA defines the ''genetic information'' that, in Congress's view, places people's civil rights at risk. This definition includes all information from genetic tests on a person or the person's family members, as well as data on manifest disease in the family members. 16 That is far broader than the subset of test results that have a well-understood clinical or reproductive significance. Before GINA, bioethicists debated whether unconfirmed, subclinical-quality genetic test results were even genetic ''information.'' 17 Although there are a range of bioethical perspectives on this question, there is a fairly broad consensus within the bioethics community that laypeople can be harmed by access to subclinical-quality genomic data.
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The GINA statute recognizes that unconfirmed or uncertain genetic test results have a civil-rights significance, even when they lack clinical significance. People might suffer discrimination if results from another, sicker person are wrongly attributed to them by a laboratory mix-up. Law enforcement might link them to a crime if a research laboratory stores their forensic CODIS markers in its files, and the laboratory's certificate of confidentiality would not always protect them. 18 Some lawyers believe that the position of the CMS is inconsistent with the CLIA statute, but the practical reality is that a federal regulatory agency's position, whether or not it is correct, ''still establishes the law for all those unwilling to pay the expense, or suffer the ill-will of challenging the agency in court.'' 31 Moreover, it is not clear that research laboratories have any rational incentive to challenge the position of the CMS. Providing HIPAA access is troublesome and costly: the HHS estimated that laboratories nationwide will collectively incur costs of up to $63 million per year to respond to HIPAA access requests. 1 It is plausible that research laboratories that store genomic data could be hit with a disproportionate share of these access requests because people find genomic data intriguing. Laboratories operating under the CLIA research exception understandably might not wish to challenge the view that these amendments tie their hands with respect to HIPAA access. The position of the CMS has had the practical effect of making it harder for research participants to exercise their HIPAA access right. Research participants face an uphill battle, because the HIPAA and CLIA statutes both lack a so-called private right of action 32, 33 that lets citizens sue to protect their own civil rights, so they depend on regulators to protect them.
Reconciling Safety and Civil Rights
As the federal regulatory agenda expanded after GINA, competing safety and civil-rights regulatory objectives were not successfully integrated. These objectives point to different policies on specific issues, such as whether individual access to genomic data should be narrow or broad. When consumer safety and civil rights collide, safety regulators must carefully craft safety solutions that preserve people's civil rights. Section 242 of Title 18 of the US Code exemplifies the high priority that civil rights receive in the American system of law: state and federal regulators cannot take actions ''under the color of any law'' that would ''willfully subject any person . to the deprivation of any rights . protected by the Constitution or laws of the United States.'' 34 HIPAA access is the sort of right that section 242 aims to protect: it is a right protected by federal law, and it enables the exercise of various other civil rights, including some constitutional rights. The Department of Justice emphasizes that section 242 protects civil rights broadly and is not limited to traditional civil-rights abuses ''motivated by animus toward the race, color, religion, sex, handicap, familial status or national origin of the victim.'' 35 The civil rights that GINA and HIPAA protect are well within its scope. Actions under the color of law include acts that public officials perform lawfully, as well as acts ''done while the official is purporting to or pretending to act in the performance of his or her official duties. '' 35 This means that it is largely beside the point to debate whether the FDA and CMS have legal authority to block HIPAA access. Whether they do or do not, they are expected to fulfill their consumer safety responsibilities in a way that protects people's civil rights, including people's right to access their own data.
Suppose, hypothetically, that patients of Polynesian ancestry experience a high rate of serious drug-related injuries when prescribed a particular FDA-approved drug. The FDA has legal authority, at section 355-1(f) (3) of Title 21 of the US Code, to impose use restrictions on drugs. Should the FDA use this power to block physicians from prescribing the drug to patients of Polynesian ancestry? Of course not. Doing so would violate the patients' civil rights, unless the FDA has proof that every single one of them will suffer the injury, and maybe not even then because they are autonomous agents with different preferences for benefits and risk. The FDA has other tools to address safety risks without blocking access: warnings in drug labeling, medication guides to inform patients directly, ''Dear Doctor'' letters for physicians, or postmarketing studies to clarify who is at risk. Federal law requires agencies to craft safety solutions that preserve civil rights.
This fact matters most with respect to data generated in the past at research laboratories operating under the CLIA research exception, 29 although it also affects the vast array of subclinical-quality findings that clinical laboratories generate as a byproduct of detecting the 200 or so variants that, under current scientific understanding, have a known clinical significance. 36 Some observers call for all research laboratories simply to comply with CLIA. Even if research laboratories complied with CLIA prospectively, however, this would not resolve problems with data generated in the past, which can never be made CLIA compliant. So long as old test results are stored and shared for secondary uses, they potentially affect people's civil rights, and individuals need access. There are various civilrights-respecting ways to address safety concerns, such as requiring laboratories to disclose problems with data quality or to warn consumers not to use research-quality data for medical decisions without confirmation. Regulators could send ''Dear Doctor'' letters instructing clinicians that low-quality HIPAA access data are in circulation and to resolve doubts about data provenance in favor of retesting. Regulators could use their public information power to publish reliability scores for the many available genomic interpretation services to help steer the public to good ones. The deeper problem with requiring all research laboratories to comply with CLIA is that CLIA would not resolve concerns about the quality of research data. Congress enacted the CLIA statute after problems with cervical cancer screening 37 This is not to deny that the safety of clinical laboratory testing has improved after CLIA, but the research exception exists for good reason and should not be abandoned without careful, reality-based deliberation. This commentary's reference to section 242 was simply to explain the priority that federal civil-rights laws enjoy in relation to other laws. It was not to suggest that any agency has violated ityet. Section 242 addresses willful violations of people's civil rights. Recent barriers to access appear to be the product of a well-intentioned misunderstanding about what the HIPAA access right is.
The Ethical Imperative of Individual Access Discourse about HIPAA access sometimes conveys a tone of shocked indignation, as if the access right burst out of nowhere and took everybody by surprise. In fact, HIPAA access codifies long-standing ethical principles enunciated in analyses that Congress commissioned at the dawn of the information age in the 1970s 42 and again in the late 1990s. 43 In both cases, legislators were grappling with how to protect people's rights in an age when storing, sharing, and using personal data offered important societal benefits, and both studies converged on two ethical principles. First, people cannot grant valid informed consent for their data to be used in research if they do not know what their records contain, 43 so individual access facilitates socially beneficial data access. Second, there is sometimes ethical justification for using people's data without consent, but unconsented access implies the need for an individual access right so that people can at least understand and mitigate the resulting risks to their civil rights. 42 The Privacy Protection Study Commission's 1977 report specifically examined access to research data and concluded that if research records cannot be ''totally protected against the possibility that individually identifiable information in them will be disclosed for any other purpose, the individual's concern is obvious and his access right highly relevant.'' 42 If policy makers feel that the safety risks of HIPAA access to research data are unacceptable, they can block it prospectively by moving genomic research to non-HIPAA-covered laboratories. There is no access right there. This implies, however, that privacy and data-security policies for genomic research would need to become far stronger than the protections that HIPAA currently provides. HIPAA's access right is a civil-rights safety net that helps people protect themselves in the face of various HIPAA provisions that leave their civil rights at risk: for example, unrestricted sharing of de-identified data, the lack of mandatory restrictions on downstream re-identification and redisclosure, and the use of institutionalreview-board-approved waivers to effectuate research access to people's data without their permission. These same HIPAA provisions enable socially beneficial uses of data and foster the creation of large-scale data commons to advance public health, precision medicine, and genomic research. 44, 45 Taking people's access away would imply that they need tighter control over their data to protect their civil rights. Goodbye, genomic data commons.
Conclusion
HIPAA's access right is a federal civilrights law. As such, it merits special respect and care. In GINA, Congress authorized the OCR to make regulations to protect genomic civil rights. Federal law constrains how far other regulators can go to interfere with these rights. Debate about the access right should focus on crafting civilrights-preserving strategies to address valid, evidence-backed safety concerns. Financial impacts on research laboratories also bear close monitoring. For research laboratories, HIPAA access is an ongoing, unfunded federal civil-rights mandate. Congress created genomic civil rights and might need to authorize funds to help-not just during research grants but also after grants end. Americans who are old enough still recall the heated debate after Congress passed the 1965 Voting Rights Act. Respected civic and spiritual leaders and grandfathers we loved voiced deep ethical convictions that eliminating literacy tests would subject voters and society to ill-informed decisions and risks of harm. This author's views are biased by having seen, before the age of 6, that highly ethical people can be wrong about civil rights.
